Vivere develops targeted cancer therapies that activate the immune system to detect and destroy tumors using engineered bio-platforms.
Vivere Oncotherapies has raised $10.0M in total funding. The most recent round was Seed. The last funding was announced in January 2026.
Vivere Oncotherapies's investors include Alumni Ventures, Pillar VC, Freeflow Ventures, Berkeley Frontier Fund, National Cancer Institute.
Vivere Oncotherapies is headquartered in Berkeley, United States.
Vivere develops targeted cancer therapies that activate the immune system to detect and destroy tumors using engineered bio-platforms.
Vivere Oncotherapies is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vivere Oncotherapies — Funding & Investors." VCBacked, January 13, 2026, https://www.vcbacked.co/company/vivere-oncotherapies. Accessed September 30, 2026.
VCBacked. (2026). Vivere Oncotherapies — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/vivere-oncotherapies
{{cite web |title=Vivere Oncotherapies — Funding & Investors |url=https://www.vcbacked.co/company/vivere-oncotherapies |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated